Retrospective, observational, multicentric study of a CTD-ILD cohort from 30 centers in Argentina, Uruguay and Spain, describing demographic, functional, radiological characteristics, applied treatments, evaluating progression and response to therapy based on respiratory functionalism (LFT). Evolution was analyzed according to the variation of %FVC according to the baseline at 6-12 months of IT. Progression: %FVC fall >10%. Stability: variation of %CVF <10% (rise or fall). Results: Table 1. Characteristics HRCT, %FVC, %DCO, IT, severe infections and death. Conclusions: -Early immunosuppressive therapy (IT) can modify the evolution of CTD-ILD: there is a statistical association between late IT and LFT deterioration. -%79 of patients showed improvement or stability after treatment. -%26.5 of the patients with CTD-ILD presented progression despite immunosuppression, while inflammatory myopathies and other CTDs showed a better response.
Rationale: Patients with acute symptomatic pulmonary embolism (PE) deemed to be at low risk for early complications might be candidates for partial or complete outpatient treatment.Objectives: To develop and validate a clinical prediction rule that accurately identifies patients with PE and low risk of short-term complications and to compare its prognostic ability with two previously validated models (i.e., the Pulmonary Embolism Severity Index [PESI] and the Simplified PESI [sPESI])Methods: Multivariable logistic regression of a large international cohort of patients with PE prospectively enrolled in the RIETE (Registro Informatizado de la Enfermedad TromboEmbólica) registry.Measurements and Main Results: All-cause mortality, recurrent PE, and major bleeding up to 10 days after PE diagnosis were determined. Of 18,707 eligible patients with acute symptomatic PE, 46 (0.25%) developed recurrent PE, 203 (1.09%) bled, and 471 (2.51%) died. Predictors included in the final model were chronic heart failure, recent immobilization, recent major bleeding, cancer, hypotension, tachycardia, hypoxemia, renal insufficiency, and abnormal platelet count. The area under receiver-operating characteristic curve was 0.77 (95% confidence interval [CI], 0.75–0.78) for the RIETE score, 0.72 (95% CI, 0.70–0.73) for PESI (P < 0.05), and 0.71 (95% CI, 0.69–0.73) for sPESI (P < 0.05). Our RIETE score outperformed the prognostic value of PESI in terms of net reclassification improvement (P < 0.001), integrated discrimination improvement (P < 0.001), and sPESI (net reclassification improvement, P < 0.001; integrated discrimination improvement, P < 0.001).Conclusions: We built a new score, based on widely available variables, that can be used to identify patients with PE at low risk of short-term complications, assisting in triage and potentially shortening duration of hospital stay.
La hipertension arterial es el principal factor de riesgo de orbimortalidad cardiovascular. En los ultimos anos se generaron numerosas recomendaciones con respecto al manejo de la hipertension arterial, con informacion divergente entre ellas y muchas de ellas realizadas en paises de altos ingresos con otras realidades socioeconomicas y pidemiologicas. En general, pocas recomendaciones referidas al manejo de la hipertension arterial surgen de la clinica medica, especialidad que permite la mirada holistica e integrada de los problemas de salud del adulto. Los problemas que se asocian a un control deficitario de la hipertension arterial son: subutilizacion del tratamiento farmacologico, baja tasa de pacientes tratados con estrategia combinada, falta de prescripcion adecuada de los cambios en el estilo de vida, baja adherencia terapeutica e inercia clinica. En la presente publicacion se presentan recomendaciones efectuadas por especialistas en clinica medica/medicina interna para el manejo de la hipertension arterial en adultos.Palabras clave. Hipertension arterial, guias, recomendaciones, morbilidad cardiovascular, mortalidad cardiovascular, farmacos antihipertensivos, adherencia, monoterapia, terapia combinada, inercia clinica, estilos de vida.SUMMARY OF SAM GUIDELINES ON THE MANAGEMENT OF HYPERTENSION IN ADULTSAbstractHypertension is the main risk factor for cardiovascular morbidity and mortality. Over the last years, several guidelines have been published regarding the management of arterial hypertension, with divergent information among them and many of them carried out in high-income countries, with their own socioeconomic and epidemiological realities. In general, few guidelines regarding the management of arterial hypertension arise from the medical clinic, specialty that allows a holistic and integrated view of health issues in the adult. There are problems associated with poor control, such as underutilization of pharmacological treatment, low rate of patients treated with a combined strategy, lack of adequate prescription of changes in lifestyle, low therapeutic adherence and clinical inertia. This article presents guidelines made by medical clinic/internal medicine specialists for the management of hypertension in adults.Key words. Hypertension, guidelines, recommendations, cardiovascular morbidity, cardiovascular mortality, antihypertensive drugs, adherence, monotherapy, combination therapy, clinical inertia, lifestyles.
To compare the efficacy, toxicity and glucocorticoid (GC)-sparing effects of intravenous cyclophosphamide (iv CYC) with other immunosuppressive regimes as the induction treatment for Idiopathic Inflammatory Myopathy-Related Interstitial Lung Disease (IIM-ILD). Observational comparative study of patients with IIM-ILD from the EPIMAR and Cruces cohorts. The main efficacy outcome was a 6 to 12-month improvement >10% in the forced vital capacity (FVC) from baseline. Overall, 47 patients were included: 22 (47%) in the CYC group and 25 (53%) in the non-CYC group (32% azathioprine, 28% GC alone, 20% mycophenolate, 16% calcineurin-inhibitors and methotrexate and 4% rituximab). 81% patients were female with a mean age of 50.4 years. FVC improvement was achieved by 64% patients in the CYC group vs. 32% in the non-CYC group (p = 0.03). In the logistic regression model, CYC was identified as the only independent predictor of FVC improvement (OR=3.97, 95% CI 1.07–14.75). Patients in the CYC group received more methyl-prednisolone pulses (MP) (59% vs. 28% in the non-CYC group, p = 0.03), less initial GCs doses >30 mg/d (19% vs. 77%, p = 0.001) and lower 6-month average doses of prednisone (11 mg/d vs. 31.1 mg/d, p = 0.001). iv CYC showed better functional outcomes than other immunosuppressants in IIM-ILD. The additional use of MP is likely to potentiate the effects of CYC and allows lowering prednisone doses. Therefore, CYC in combination with MP could be considered as the first line induction therapy in IIM-ILD, without limiting its use to rapidly progressive, life-threatening or refractory disease.